4 MNCs among top 10 companies with dividend-earning promoters in FY15.
Paid Rs 15,474 cr against CIL's Rs 13,075 cr in FY15
This was even as the country's economy grew by 7.3%.
23 Nifty companies reported an annual decline in net profit.
RIL is also more profitable than Tata Motors.
FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.
World trade has been growing slower than world GDP since 2012.
The company received a fresh equity infusion in 2012-13.
Many analysts find market expensive, even at current levels.
Telcos have indicated that rates will have to be raised, as higher volumes alone will not suffice to meet the higher costs.
There, however, has been an improvement in operating margins.
The challenge of merging Ranbaxy into the company has not been factored in.
Tech major's shareholders will receive total dividend of Rs 15,474 crore in FY15
For equity investors, the risk-to-reward ratio is worsening.
It was a year of big gains for equity investors.
Corporates' forex borrowings have grown at a CAGR of 15.6% since 2008.
Corporate India at present is more indebted than all state govts put together.
Given the better growth in JLR sales and improving domestic sales, nearly 90 per cent of the analysts covering the stock have a 'Buy' rating.
Through the past 12 months, the Bank Nifty has risen 55%
Dilip Shanghvi founded Sun Pharma in 1983.
